Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. | Eisai plans to lay off 121 employees in the U.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98. The firm has a market capitalization of $11.36 billion, a price-to-earnings ratio of 34.64 and a beta of 0.33.

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...

In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” In case you ...

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock ...